Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2006-07-06 Investor Presentation
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Updated Investor Presentation 27 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed presentation containing forward-looking statements, product pipeline information, clinical trial updates, marketing status, and financial data including balance sheet and income statement figures. It references filings with the US Securities and Exchange Commission (Form 20-F) but is not itself a regulatory filing or certification. The content is consistent with an investor presentation focusing on financials, strategy, and market position rather than a formal annual report or earnings release. The length (15,000 characters) and detailed content support this classification. Therefore, the document is best classified as an Investor Presentation (IP).
2006-07-06 English
First commercial supply of Aridol to US Market 2 pages ?Kb
Capital/Financing Update Classification · 90% confidence The document is an ASX/Media release dated 30 June 2006 announcing Pharmaxis' first commercial supply of Aridol to the U.S. market. It discusses a purchase order for test kits, clinical trials, regulatory approvals, and company background. There are no financial statements, detailed financial performance data, or comprehensive management discussion of results. The document is a corporate announcement about a commercial milestone and product supply, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best as a Capital/Financing Update (CAP) because it relates to commercial supply and market entry activities, which are capital/financing related corporate updates. Therefore, the classification is CAP with high confidence.
2006-06-29 English
Appendix 3B-Employee Options 9 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about the issuance of unlisted employee options, exercise prices, expiry dates, and the number of securities issued or to be issued. The document references ASX (Australian Securities Exchange) rules and includes specifics about securities classes, issue prices, and the purpose of the issue. This type of document is a formal announcement related to capital raising or changes in capital structure, specifically the issuance of new securities. It is not a full financial report, audit, or management discussion, nor is it a voting result or legal proceeding. The content aligns with announcements about new share issues or capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (15,000 characters) and detailed content confirm it is not merely an announcement of a report but a substantive filing about securities issuance.
2006-06-05 English
Appendix 3B 9 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) announcement for new issue announcements, application for quotation of additional securities, and agreements related to securities issuance. It details the issuance of ordinary shares upon exercise of options under an employee option plan, including number of shares, issue price, and terms. This type of document is a capital/financing update related to share issuance and capital structure changes. It is not a full financial report, earnings release, or management discussion, but a regulatory announcement about capital changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support a confident classification.
2006-06-05 English
Change of Director's Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Change of Director's Interest Notice' and references Appendix 3Y and ASX listing rule 3.19A.2. It details a director's acquisition of shares, including dates, number of securities, and value. This is a report of personal share transactions by a company director. There is no financial performance data, earnings information, or management discussion. The content matches the definition of Director's Dealing filings, which report insider trades by directors and executives.
2006-05-07 English
Appendix 3B 9 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including the number of securities, issue price, and dates. The document references ASX (Australian Securities Exchange) rules and is structured as a formal announcement of a securities issue. There are no financial statements, management discussion, or earnings data present. The content is focused on capital issuance and related securities information. Therefore, this document fits the category of a Capital/Financing Update (CAP).
2006-05-04 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.